Finance ❯ Stock Market ❯ Investment Analysis ❯ Pharmaceutical Stocks

Novo Nordisk A/S

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Full results will be presented at next week’s CTAD meeting after the company canceled a planned one-year extension.